7527-65-3

Basic information

• Product Name: 1-(cyclohexylamino)-2-methylpropan-2-ol
• CAS NO: 7527-65-3
• Molecular Formula: C₁₀H₂₁NO
• Molecular Weight: 171.2798
• Mol File: 7527-65-3.mol

Chemical Properties

• Boiling Point: 285.2°C at 760 mmHg
• Flash Point: 97.5°C
• Density: 0.94g/cm³
• Vapor Pressure: 0.000326mmHg at 25°C
• Refractive Index: 1.478
• CAS DataBase Reference: 1-(cyclohexylamino)-2-methylpropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(cyclohexylamino)-2-methylpropan-2-ol(7527-65-3)
• EPA Substance Registry System: 1-(cyclohexylamino)-2-methylpropan-2-ol(7527-65-3)

Safety Data

• Hazardous Substances Data: 7527-65-3(Hazardous Substances Data)

Usage

Uses

Used in Nuclear Reprocessing:
CMPO is used as a chelating ligand for the extraction and separation of actinide and lanthanide elements from aqueous solutions in the nuclear reprocessing industry. Its high affinity for specific metal ions allows for efficient and selective extraction processes, which is crucial for the effective management and utilization of nuclear materials.
Used in Metal Extraction from Industrial and Mining Waste Streams:
CMPO is employed in the development of solvent extraction processes for the recovery of valuable metals from industrial and mining waste streams. By facilitating the selective extraction of metal ions, CMPO contributes to the sustainable management of resources and the reduction of environmental impact associated with metal extraction and processing.
Used in the Development of Advanced Metal Extraction Technologies:
CMPO is utilized in the research and development of innovative metal extraction technologies. Its unique properties as a chelating ligand make it an essential component in the design and optimization of new processes for the efficient and environmentally friendly recovery of metals from various sources.

Upstream product

• 108-94-1 cyclohexanone 
• 2854-16-2 1-Amino-2-methyl-propan-2-ol 
• 100812-05-3 2,2-Dimethyl-propionic acid 2-[(E)-cyclohexylimino]-1,1-dimethyl-ethyl ester 
• 558-30-5 2-methyl-1,2-epoxypropane 
• 108-91-8 cyclohexylamine 
• 1379226-90-0 C₁₀H₁₉NO 
• 5857-80-7 (Z)-N-(2-methylpropylidene)cyclohexanamine oxide 
• 25100-12-3 N-cyclohexylhydroxylamine hydrochloride 
• 7527-63-1 2,2-dimethyl-1-oxa-4-aza-spiro[4.5]decan-3-one 

Downstream Products

• 500538-09-0 diphenyl-acetic acid-[cyclohexyl-(β-hydroxy-isobutyl)-amide] 
• 854654-06-1 N-cyclohexyl-N-(β-hydroxy-isobutyl)-N'-phenyl-urea 
• 500537-44-0 4-nitro-benzoic acid-[cyclohexyl-(3-hydroxy-isobutyl)-amide] 
• 500537-46-2 N-cyclohexyl-N-(β-hydroxy-isobutyl)-benzamide 

Relevant articles and documents

Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus, and Human Rhinoviruses

Over half a century since the description of the first antiviral drug, “old” re-emerging viruses and “new” emerging viruses still represent a serious threat to global health. Their high mutation rate and rapid selection of resistance toward common antiviral drugs, together with the increasing number of co-infections, make the war against viruses quite challenging. Herein we report a host-targeted approach, based on the inhibition of the lipid kinase PI4KIIIβ, as a promising strategy for inhibiting the replication of multiple viruses hijacking this protein. We show that bithiazole inhibitors of PI4KIIIβ block the replication of human rhinoviruses (hRV), Zika virus (ZIKV) and SARS-CoV-2 at low micromolar and sub-micromolar concentrations. However, while the anti-hRV/ZIKV activity can be directly linked to PI4KIIIβ inhibition, the role of PI4KIIIβ in SARS-CoV-2 entry/replication is debated.

INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

IDO INHIBITORS

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.

Preparation of Vicinal N-Alkylamino Alcohols via Acylation-Rearrangement of Nitrones Followed by Hydride Reduction

Acylation-rearrangement of N-tert-butyl and N-cyclohexyl nitrones of cyclohexanecarboxaldehyde (1), n-butyraldehyde, isobutyraldehyde, 3-cyclohexenecarboxaldehyde, and α-methylpropionaldehyde gave α-pivaloyloxy imines, which underwent reduction with lithi